Huadong Medicine targets infringement of "Suyan Zhen"! What's the deal with the confrontation of the two "Girl Needle" from a distance?

① “Yi Yanshi”, a subsidiary of Huadong Pharmaceutical, claims that Cai Cai Medical's “Su Yan Zhen” infringes on its invention patent rights and has now filed a civil lawsuit; ② Gu Yuchun, the parent company of Cai Cai Medical, has denied this claim. Up to now, “Su Yan Zhen” has been on the market for less than two months; ③ Industry insiders believe that it is now difficult to define whether Gu Yuchun is infringing.

cls.cnOct 12 08:24 ET

Controlling shareholder's high pledge rate is questioned, Tonghua Dongbao: revenue will recover quarterly in the second half of the year | Directly hit the earnings conference

① The high pledge rate of shares held by Tonghua Dongbao's controlling shareholder was questioned. Li Jiahong, chairman of the company, said that it was due to the long investment project cycle of Dongbao Group; ② In terms of performance, Li Jiahong expects the company's revenue to recover quarterly in the second half of the year; ③ the company also explained the sales situation of new products.

cls.cnOct 10 05:26 ET

The first third-quarter forecast of the star board: Peptide active pharmaceutical ingredients 'hot selling', Nuotai biology's net profit increase reaches up to 181%.

①Nuote Bio is the first to release the performance forecast for the third quarter of 2024, benefiting from the sales growth of peptide active pharmaceutical ingredients, with an expected net income attributable to shareholders of 0.1 billion yuan to 0.14 billion yuan, a year-on-year increase of 100.56% to 180.78%. ②Nuote Bio is expanding its peptide workshop to meet the hot demand for GLP-1, expecting to further increase peptide production capacity by 10 tons per year by the first half of 2025.

cls.cnOct 7 21:21 ET

Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.

①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.

cls.cnSep 11 03:59 ET

2024 Financial Report | After breaking through 40 billion dollars in revenue, how can Huadong Pharmaceutical face the challenge of “deceleration”

Big dividends

wallstreetcnApr 18 23:33 ET

Backed by Huadong Pharmaceutical, Quanxin Biotech's All in the Field of Self-Immunity | Insight Research

Through a hearing on the Hong Kong Stock Exchange, the secondary market also welcomed a major free player.

wallstreetcnFeb 28 20:25 ET